In the rapidly evolving landscape of emerging biomarkers for immunotherapy, tumor mutational burden (TMB) is very promising as a predictive biomarker and potentially could lead the way for precision immuno-oncology. In this context, this focused issue of Translational Lung Cancer Research(TLCR) aims to capture the progress, challenges, limitations and perspectives to understand the measurement methods and clinical significance of TMB in patients with lung carcinoma.
